Clinical trials: Cerebral Disorder
Chronic Pain, Brain Injuries, Traumatic
Telehealth Pain Self-Management for Employed Adults
The E-TIPS trial will evaluate an evidence-based, telehealth pain self-management intervention compared to standard care (a waitlist) for chronic pain in adults with physical disabilities who are employed.
- Conditions
- Chronic Pain, Brain Injuries, Traumatic, Multiple Sclerosis, Spinal Cord Injuries
- Trial name
- E-TIPS (NCT04248725)
- Testing
- E-TIPS
- Where
- United States
- Volunteers
- 220 people
- Sponsor
- University of Washington
Partial Seizures
Evaluating the Efficacy and Safety of Zonisamide in the Treatment of Partial Seizures
The objectives of this trial are to evaluate the safety and efficacy of Zonisamide as adjunctive therapy in medically refractory patients receiving other antiepileptic drugs (AEDs).
- Trial name
- NCT00327717
- Testing
- Zonisamide
- Where
- 8 sites in China
- Volunteers
- 240 people
- Sponsor
- Eisai Inc.
Spinal Cord Injury, Autonomic Dysreflexia
Treatment of Post-SCI Hypotension
While treatment strategies for OH have been identified for use in persons with acute SCI, the field of SCI medicine lacks a gold standard for treatment thresholds and well-defined outcome parameters.
- Conditions
- Spinal Cord Injury, Autonomic Dysreflexia, Orthostatic Hypotension, Baroreceptor Integrity
- Trial name
- NCT02919917
- Testing
- Midodrine Hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 66 people, healthy volunteers welcome
- Sponsor
- James J. Peters Veterans Affairs Medical Center
Non Small Cell Lung Cancer, Small Cell Lung Cancer
Study of Enzastaurin Versus Placebo in the Treatment of Patients With Brain Metastases of Lung Cancer, After Whole Brain Radiation Therapy
This study is a multinational study to compare enzastaurin versus placebo in the treatment of patients with brain metastases of lung cancer.
- Trial name
- NCT00415363
- Testing
- enzastaurin
- Where
- 7 sites in Denmark, Norway and 3 more
- Volunteers
- 109 people
- Sponsor
- Eli Lilly and Company
Alzheimer's Disease
Safety and Tolerability of Memantine in Moderate to Severe Alzheimer's Disease
The primary objective of the study was to examine the safety and tolerability of memantine in outpatients with moderate to severe Alzheimer's Disease.
- Trial name
- NCT00857233
- Testing
- Memantine
- Where
- 33 sites in Canada
- Volunteers
- 297 people
- Sponsor
- H. Lundbeck A/S
Epilepsy
Assessing The Long-Term Safety And To Explore The Long-Term Efficacy Of Zonisamide As Monotherapy In Newly Diagnosed Partial Seizures
The purpose of this study is to assess the long-term safety and tolerability and to explore the long-term efficacy of zonisamide as monotherapy treatment in subjects with newly diagnosed partial seizures.
- Trial name
- NCT00848549
- Testing
- Zonisamide, Carbamazepine
- Where
- 133 sites in Australia, Denmark and 18 more
- Volunteers
- 295 people
- Sponsor
- Eisai Inc.
Huntington's Disease
Open Label Extension Study To Investigate Long Term Safety, Tolerability And Efficacy Of Pf-02545920 In Subjects With Huntington's Disease Who Completed Study A8241021
This study is a 12 month open label extension study of PF-02545920 20 mg dosed BID following study A8241021 in subjects with HD. Primary endpoints will be to assess long-term safety and tolerability of 20 mg BID of PF-02545920.
- Trial name
- NCT02342548
- Testing
- 20 mg BID of PF-02545920
- Where
- 50 sites in United States, Canada and 3 more
- Volunteers
- 188 people
- Sponsor
- Pfizer
Intracranial Aneurysm
Pipeline™ Vantage Embolization Device With Shield Technology™ for Wide-Necked Intracranial Aneurysms (ADVANCE)
The purpose of this study is to assess the safety and effectiveness of the Pipeline™ Vantage Embolization Device with Shield Technology™ in the treatment of intracranial aneurysms within the intended indication for use.
- Trial name
- ADVANCE (NCT03873714)
- Testing
- Pipeline™ Vantage Embolization Device with Shield Technology™
- Where
- 3 sites in United States
- Volunteers
- 14 people
- Sponsor
- Medtronic Neurovascular Clinical Affairs
Hepatitis C
Cerebral Effects of Pegylated Interferon in Hepatitis C Positive Subjects
The hypothesis of this study is that pegylated interferon would cause cognitive deficits and mood changes in hepatitis C (HCV) positive subjects.
- Trial name
- NCT00136214
- Testing
- MR brain and neuropsychiatric tests
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Beth Israel Deaconess Medical Center
Fabry Disease
Switch Over Study of Biosimilar Agalsidase Beta for Fabry Disease
BIO-AGA-Fase III-001 is a Phase III, prospective, multicenter, open-label, single-group, baseline-controlled, switch over clinical trial to evaluate the efficacy and safety of AGA BETA BS in patients with FD already treated and…
- Trial name
- SMILE (NCT05843916)
- Testing
- Recombinant human alpha galactosidase A (agalsidase beta), Recombinant human alpha-galactosidase A (agalsidase beta)
- Where
- 5 sites in Argentina
- Volunteers
- 20 people
- Sponsor
- Bio Sidus SA
Idiopathic Parkinson's Disease
Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease
The purpose of this study was to evaluate the safety and potential benefits of CERE-120 in the treatment of Parkinson's disease.
- Trial name
- NCT00985517
- Testing
- CERE-120: Adeno-Associated Virus Delivery of Neurturin
- Where
- 11 sites in United States
- Volunteers
- 57 people
- Sponsor
- Sangamo Therapeutics
Stroke
Patient Targeted Upper Extremity Rehabilitation After Stroke
Each year in the US, approximately 795,000 people have a stroke, and the overwhelming majority of those who survive are unable to resume meaningful daily activities because of impaired movement in one arm/hand.
- Trial name
- TARG (NCT01819506)
- Testing
- Task Practice Physical Rehabilitation Therapy
- Where
- United States
- Volunteers
- 103 people
- Sponsor
- VA Office of Research and Development
Huntington Disease
Within Subject Crossover Study of Cognitive Effects of Neflamapimod in Early-Stage Huntington Disease
This is a double-blind, placebo-controlled 2-period 10-week treatment within-subject crossover study of neflamapimod in early-stage Huntington disease (HD).
- Trial name
- NCT03980938
- Testing
- neflamapimod
- Where
- United Kingdom
- Volunteers
- 15 people
- Sponsor
- EIP Pharma Inc
Hepatic Encephalopathy
Evaluation of Rifaximin SSD for Delaying Encephalopathy Decompensation in Patients With Cirrhosis
Study RNLC3132 is a Phase 3, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of rifaximin SSD-40mg IR for the delay of the first episode of overt hepatic encephalopathy (OHE)…
- Trial name
- RED-C-3132 (NCT05297448)
- Testing
- Rifaximin SSD
- Where
- 188 sites in United States, Australia and 15 more
- Volunteers
- 517 people
- Sponsor
- Bausch Health Americas, Inc.
Essential Tremor, Parkinson's Disease
Compare Rates of Agreement Between Clinical Diagnosis and Visual Assessment of DaTscan™ Images in Non-Caucasian and Caucasian Subjects With Parkinson's Disease (PD) or Essential Tremor (ET)
The primary objective of this study is to determine if the diagnostic performance of DaTscan™ single photon emission computed tomography (SPECT) imaging is different in non-Caucasian subjects compared with Caucasian subjects with…
- Trial name
- NCT01952678
- Testing
- DaTscan™ - Non-Caucasian Participants, DaTscan™ - Caucasian Participants
- Where
- United States
- Volunteers
- 204 people
- Sponsor
- GE Healthcare
Parkinson Disease
A Study to Evaluate the Efficacy of 18 to 24mg/Day Ropinirole Controlled Release (CR) Tablets in Early and Advanced Parkinson's Disease (PD) Patients.
This study is a Phase III, multicentre, randomized, initial double-blind study with subsequent open label phases. The study will havea screening phase (4 weeks), a dose increase effect verification phase (12 weeks), a down…
- Trial name
- NCT01929317
- Testing
- Ropinirole CR 2mg tablet, Ropinirole CR 8mg tablet
- Where
- 17 sites in Japan
- Volunteers
- 81 people
- Sponsor
- GlaxoSmithKline
Migraine
To Evaluate the Blockade of CGRP in Preventing PACAP-38 Induced Migraine-like Attacks With AMG 334 in Migraine Patients
Phase I, Randomized, Parallel-group, Double-Blind, Placebo-Controlled, Single Dose Study to Evaluate the Blockade of CGRP Receptor by AMG 334 in Preventing PACAP-38 Induced Migraine-like Attacks in Migraine Patients.
- Trial name
- NCT02542605
- Testing
- Erenumab, PACAP-38 Challenge Agent
- Where
- 3 sites in United States, Belgium and 1 more
- Volunteers
- 35 people
- Sponsor
- Amgen
Stroke, Hemiparesis
Contralaterally Controlled FES of Arm & Hand for Subacute Stroke Rehabilitation
Impaired arm and hand function is one of the most disabling and most common consequences of stroke. The Investigators have developed Contralaterally Controlled Functional Electrical Stimulation (CCFES), an innovative…
- Conditions
- Stroke, Hemiparesis, Hemiplegia
- Trial name
- NCT01688856
- Testing
- Electrical Stimulator
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- MetroHealth Medical Center
Dizziness, Brain Injury
Vestibular Consequences of Blast-related Mild Traumatic Brain Injury (TBI)
The purpose of this project is to determine the effects of mild traumatic brain injury and blast exposure on the inner ear balance and central nervous systems.
- Trial name
- NCT01021137
- Where
- United States
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- VA Office of Research and Development
Epilepsy
Open-label Extension Study of the Phase 3 VRX-RET-E22-301 Double-Blind Trial
The purpose of this study is to evaluate the safety and tolerability of long-term therapy with retigabine administered as adjunctive therapy in adult epilepsy patients with partial-onset seizures, who completed the…
- Trial name
- NCT00310375
- Testing
- Ezogabine: USAN Retigabine (International Nonproprietary Name)
- Where
- 51 sites in United States, Argentina and 3 more
- Volunteers
- 181 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.